OpenAI Cracks the Bioweapon Door

🔥 What happened OpenAI launched GPT-Rosalind-6, a reasoning model for biology and drug discovery built on the same weights as GPT-6 Astra. It refuses fewer dual-use biological queries but is gated behind an application process with security reviews. 💡 Why it matters On MedChemBench, scores jump from 28.9% to 49.6%; on GeneBench Pro, single-attempt success rises from 16.7% to 37.7%. OpenAI classifies it as High capability in biology—just below the Critical threshold. This isn't a lab toy; it's a tool that could help experts design dangerous pathogens. ⚡ Our take OpenAI built the firewall around the model, not inside it. Who gets access is decided by an application review—a dangerous precedent for 'trusted access' to dual-use AI.